Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
The new program includes upstream and downstream process development and large-scale GMP production.
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Amarex Clinical Research guides its client to phase II of FDA trials
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
New Director supports NASDAQ rule on diversity
Sam Samad will be departing Illumina on July 8, 2022, after serving as CFO for more than five years.
Subscribe To Our Newsletter & Stay Updated
